Physician profile
Mark D Oxman
NPI 1417921958
$2,818.71
in general payments reported to CMS, 2019-2025
25 companies · $912 in 2025
The $912 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,011 · 2020: $77.81 · 2021: $113 · 2022: $167 · 2023: $287 · 2024: $251 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421 · Education: $29.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,421.01 |
| Education | $29.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $822.22 | 2019-2020 | |
| Amgen INC. | $342.19 | 2023-2025 | Tavneos, Parsabiv |
| Travere Therapeutics, INC. | $292.48 | 2022-2025 | |
| Nxstage Medical, INC. | $226.27 | 2021-2025 | Nxstage System One, Liberty Select Cycler, Pureflow Sl |
| Novartis Pharmaceuticals Corporation | $202.68 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.95 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $116.65 | 2019-2025 | Velphoro |
| Calliditas Therapeutics US INC. | $101.38 | 2023-2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $74.99 | 2019 | |
| Opko Pharmaceuticals, LLC | $66.48 | 2022-2025 | Rayaldee |
| Akebia Therapeutics INC | $63.69 | 2019-2023 | Auryxia |
| Horizon Therapeutics Plc | $47.27 | 2020-2023 | Krystexxa |
| Ardelyx, INC. | $35.47 | 2025 | Ibsrela |
| Vifor Pharma, INC. | $35.02 | 2020-2023 | Veltassa, Korsuva |
| Janssen Scientific Affairs, LLC | $33.16 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $30.21 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.56 | 2024-2025 | Jardiance |
| Baxter Healthcare | $27.90 | 2019 | |
| Alexion Pharmaceuticals, INC. | $27.33 | 2023 | Ultomiris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.74 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $23.41 | 2025 | Jynarque |
| Ultragenyx Pharmaceutical INC. | $20.97 | 2024 | Crysvita |
| Aurinia Pharma U.S., INC. | $20.16 | 2021 | |
| Novo Nordisk INC | $13.51 | 2025 | Ozempic |
| Nuwellis, INC. | $4.02 | 2021-2023 | Aquadex Smartflow Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Oxman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.